 Reduction glomerular hyperfiltration normoalbuminuric IDDM patients mo aldose reductase inhibition Hyperglycemia glucose metabolism polyol pathway tissues insulin glucose uptake high level aldose reductase activity functional structural abnormalities diabetes development late complications effect aldose reductase inhibitor ponalrestat kidney function uncomplicated insulin-dependent diabetes IDDM normoalbuminuric IDDM patients mo treatment ponalrestat mean SD age yr duration yr mo placebo age yr duration yr glomerular filtration rate clearance iothalamate ponalrestat-treated patients change placebo renal plasma flow clearance hippuran urinary albumin excretion rate radioimmunoassay fractional albumin clearance renal vascular resistance unchanged groups modest increase ponalrestat unchanged placebo side effects ponalrestat inhibition aldose reductase characteristic hyperfiltration uncomplicated IDDM